Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients.

Combo-immunotherapy Immune checkpoint inhibitors Metastatic colorectal cancer Microsatellite instability high Mono-immunotherapy Overall survival Progression-free survival Total Tumor Volume

Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
16 Mar 2024
Historique:
received: 24 01 2024
revised: 04 03 2024
accepted: 10 03 2024
medline: 20 3 2024
pubmed: 20 3 2024
entrez: 19 3 2024
Statut: aheadofprint

Résumé

This retrospective study determined survival responses to immune checkpoint inhibitors (ICIs), comparing mono- (mono) and combo-immunotherapy (combo) in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) by analyzing quantitative imaging data and clinical factors. One hundred fifty patients were included from two centers and divided into training (n = 105) and validation (n = 45) cohorts. Radiologists manually annotated chest-abdomen-pelvis computed tomography and calculated tumor burden. Progression-free survival (PFS) was assessed, and variables were selected through Recursive Feature Elimination. Cutoff values were determined using maximally selected rank statistics to binarize features, forming a risk score with hazard ratio-derived weights. In total, 2258 lesions were annotated with excellent reproducibility. Key variables in the training cohort included: total tumor volume (cutoff: 73 cm A score based on total tumor volume, lesion count, the presence of peritoneal carcinomatosis, and age can guide MSI-H mCRC treatment decisions, allowing oncologists to identify suitable candidates for mono and combo ICI therapies.

Sections du résumé

BACKGROUND BACKGROUND
This retrospective study determined survival responses to immune checkpoint inhibitors (ICIs), comparing mono- (mono) and combo-immunotherapy (combo) in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) by analyzing quantitative imaging data and clinical factors.
METHODS METHODS
One hundred fifty patients were included from two centers and divided into training (n = 105) and validation (n = 45) cohorts. Radiologists manually annotated chest-abdomen-pelvis computed tomography and calculated tumor burden. Progression-free survival (PFS) was assessed, and variables were selected through Recursive Feature Elimination. Cutoff values were determined using maximally selected rank statistics to binarize features, forming a risk score with hazard ratio-derived weights.
RESULTS RESULTS
In total, 2258 lesions were annotated with excellent reproducibility. Key variables in the training cohort included: total tumor volume (cutoff: 73 cm
CONCLUSIONS CONCLUSIONS
A score based on total tumor volume, lesion count, the presence of peritoneal carcinomatosis, and age can guide MSI-H mCRC treatment decisions, allowing oncologists to identify suitable candidates for mono and combo ICI therapies.

Identifiants

DOI: 10.1016/j.ejca.2024.114020 PMID: 38502988
pubmed: 38502988
pii: S0959-8049(24)00676-2
doi: 10.1016/j.ejca.2024.114020
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114020

Informations de copyright

Copyright © 2024 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/ personal relationships which may be considered as potential competing interests: Thierry ANDRE reports consulting/advisory role and/or honoraria from Amgen, Aptitude Health, Astellas Pharma, Astrazeneca, Bristol-Myers Squibb, Gritstone Oncology, GlaxoSmithKline, Merck & Co., Inc., Merck Serono, Roche, Sanofi, Seagen, Servier, Takeda, compensation for travel, accommodation expenses from Bristol-Myers Squibb, MSD & Co., Inc, and DMC member role for Inspirna. RC has received personal fees from Bristol-Myers Squibb, Exeliom Biosciences, Enterome Bioscience, MSD Oncology, Mylan Medical, Pierre Fabre, Servier and non-financial support from Amgen, Bristol-Myers Squibb, Mylan Medical and Servier. AH reports consulting/advisory role and/or honoraria from Basilea, Debiopharm, EISAI, Incyte, QED Therapeutics, Relay Therapeutics, Servier, Tahio, AstraZeneca and Reseach Grant from Incite. Nathalie LASSAU (professor of radiology) reports grand for institute Gustave Roussy from Guerbet and fees (Speaker) from Jazz Pharmaceuticals. Other authors declare no competing interests.

Auteurs

Rémy Barbe (R)

Département d'imagerie, Gustave Roussy, Villejuif, France.

Younes Belkouchi (Y)

Laboratoire BIOMAPS, CNRS, INSERM, CEA, Université Paris Saclay, Villejuif, France; Université Paris-Saclay, Centrale-Supelec, Centre de vision numérique, Gif-Sur-Yvette, France.

Yves Menu (Y)

Département d'imagerie, Gustave Roussy, Villejuif, France; SIRIC CURAMUS, INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Paris, France; Sorbonne University, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Paris, France.

Romain Cohen (R)

SIRIC CURAMUS, INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Paris, France; Sorbonne University, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Paris, France.

Clemence David (C)

Laboratoire BIOMAPS, CNRS, INSERM, CEA, Université Paris Saclay, Villejuif, France.

Michele Kind (M)

Département d'imagerie, Institut Bergonié, Bordeaux, France.

Sana Harguem (S)

Département d'imagerie, Gustave Roussy, Villejuif, France.

Lama Dawi (L)

Département d'imagerie, Gustave Roussy, Villejuif, France.

Joya Hadchiti (J)

Département d'imagerie, Gustave Roussy, Villejuif, France.

Fatine Selhane (F)

Département d'imagerie, Gustave Roussy, Villejuif, France.

Nicolas Billet (N)

Laboratoire BIOMAPS, CNRS, INSERM, CEA, Université Paris Saclay, Villejuif, France.

Samy Ammari (S)

Département d'imagerie, Gustave Roussy, Villejuif, France; Laboratoire BIOMAPS, CNRS, INSERM, CEA, Université Paris Saclay, Villejuif, France.

Ambroise Bertin (A)

Laboratoire BIOMAPS, CNRS, INSERM, CEA, Université Paris Saclay, Villejuif, France.

Littisha Lawrance (L)

Laboratoire BIOMAPS, CNRS, INSERM, CEA, Université Paris Saclay, Villejuif, France.

Baptiste Cervantes (B)

SIRIC CURAMUS, INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Paris, France; Sorbonne University, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Paris, France.

Antoine Hollebecque (A)

Département d'Innovation Thérapeutique et Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.

Corinne Balleyguier (C)

Département d'imagerie, Gustave Roussy, Villejuif, France; Laboratoire BIOMAPS, CNRS, INSERM, CEA, Université Paris Saclay, Villejuif, France.

Paul-Henry Cournede (PH)

Université Paris-Saclay, Centrale-Supelec, Lab of Mathematics and Informatics, Gif-Sur-Yvette, France.

Hugues Talbot (H)

Université Paris-Saclay, Centrale-Supelec, Centre de vision numérique, Gif-Sur-Yvette, France.

Nathalie Lassau (N)

Département d'imagerie, Gustave Roussy, Villejuif, France; Laboratoire BIOMAPS, CNRS, INSERM, CEA, Université Paris Saclay, Villejuif, France.

Thierry Andre (T)

SIRIC CURAMUS, INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Paris, France; Sorbonne University, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Paris, France. Electronic address: thierry.andre@aphp.fr.

Classifications MeSH